NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) announced results from a post-hoc analysis of HUMIRA data in early and long-standing moderate-to-severe rheumatoid arthritis patients from three randomized, controlled trials-DE019, OPTIMA and PREMIER. The analysis evaluated the simultaneous achievement of three key treatment goals: low disease activity, normal physical function and the absence of radiographic progression at one year.
For long-standing RA patients in the DE019 trial, 19 percent of patients taking HUMIRA plus methotrexate simultaneously achieved all three key treatment goals at one year, versus 5 percent of placebo plus MTX-treated patients in the study. For early RA patients in the OPTIMA trial - those who were given open label HUMIRA plus MTX following inadequate response to 26 weeks of MTX monotherapy - 29 percent of patients simultaneously achieved all three key treatment goals at one year. This rate was comparable to what was observed in the PREMIER trial with MTX-naïve early RA patients who were treated with HUMIRA plus MTX (32 percent).
Copyright RTT News/dpa-AFX
© 2012 AFX News
